http://www.copyright link/business/health/biotechnology/mesoblast-shares-all-a-flutter-on-heart-failure-trial-success-20170410-gvhnhr
Mesoblast has impressed investors with news that almost half of the heart failure patients involved in a late stage clinical trial have been successfully protected for a whole year from a sudden or significant worsening of their condition.
Treating heart failure could be a huge opportunity for Mesoblast.
In 2016, more than 15 million patients in the seven major global pharmaceutical markets, encompassing the United States, Japan and five European countries, are estimated to have been diagnosed with chronic heart failure, according to PharmaPoint.
Those patients with damaged cardiac muscles have weak hearts that struggle to pump blood around the body and about half of those who develop heart failure die within five years of diagnosis.
However Mesoblast said on Monday that, in the strict jargon reserved for clinical trials, its phase-three trial of mesenchymal precursor cell injections in heart failure patients successfully passed "interim futility analysis". That means those patients lived for a full-year without a major cardiovascular event requiring hospitalisation, and that crucially the clinical trial should continue running.
- Forums
- ASX - By Stock
- AFR - 10 Aril 2017
http://www.copyright link/business/health/biotechnology/mesoblast-shares...
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online